China's medical products administrator approved Shenzhen Salubris Pharmaceuticals' (SHE:002294) marketing of its Taikosizumab injection for high cholesterol and mixed dyslipidemia, according to a Saturday filing with the Shenzhen bourse.
Shares closed 1% higher on Monday.
The injection is administered via a single shot every four weeks, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments